Press release
CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program
- 7 Abstracts Highlighting CytomX’s Novel Probody Platform Selected for Oral and Poster Presentations - SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"- 7 Abstracts Highlighting CytomX’s Novel Probody Platform Selected for Oral and Poster Presentations -\n SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the selection of seven presentations to be featured as part of the American Society of Clinical Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place from May 29 - May 31, 2020. The titles of the abstracts are currently available on ASCO’s 2020 Digital Scientific Program, with full abstracts, including the dates and times of presentations, scheduled for publication on May 13, 2020. A list of accepted abstracts by CytomX and its partners is provided below. ASCO 2020 Clinical Highlights From Across the CytomX Probody Portfolio Preliminary Data from Phase 1/2 Trial of CX-2029, a CD71 Targeting Probody Drug Conjugate, Partnered with AbbVie Preliminary Phase 1 Clinical Data Presented by Bristol Myers Squibb from the Ongoing First-in-Human Phase 1/2a trial of BMS-986249, a Probody Version of the anti-CTLA-4 Antibody ipilimumab Updated Data from the Phase 1/2 Trial of CX-2009, an Anti-CD166 Probody Drug Conjugate Updated Clinical Data from the Phase 1/2 Trial of CX-072, an Anti-PD-L1 Probody Therapeutic, as Monotherapy, in Selected Tumor Types and in Combination with ipilimumab “Our presence at ASCO this year highlights the strong clinical progress made by CytomX and our partners in exploring the broad potential of the novel Probody technology platform,” said Amy Peterson, M.D., chief development officer of CytomX Therapeutics. “We look forward to updating the oncology community on this progress and on next steps towards our vision of transforming the lives of patients with cancer.” CX-2029, An Anti-CD71 Probody Drug Conjugate Presentation Title: CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results from a First-in-Human Study (PROCLAIM-CX-2029) in Patients (Pts) With Advanced Cancer Session Title: Developmental Therapeutics—ImmunotherapyAbstract: 3502 Session Type: Oral Presentation CX-072, An Anti-PD-L1 Probody Therapeutic Presentation Title: PROCLAIM-CX-072: Analysis of Patients With Advanced S...